1. Modlin I, ?berg K. A Century of Advances in Neuroendocrine Tumor Biology and Treatment. 2008. Hannover: Felsenstein C.C.C.P.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (4): 934–59.
3. Borch K, Ahren B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64–73.
4. Rindi G, Azzoni C, La Rosa S et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532–42.
5. Нейроэндокринные опухоли желудочно-кишечного тракта. Принципы диагностики и лечения. Под ред. В.А.Горбуновой, А.В.Егорова, А.В.Кочаткова. М., 2009.
6. Gibril F, Schumann M, Pace A et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83: 43–83.
7. Rindi G, Azzoni C, La Rosa S et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532–42.
8. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003; 12: 153–72.
9. Borch K, Ahren B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64–73.
10. Tomassetti P, Migliori M, Caletti GC et al. Treatment of type И gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343: 551–4.
11. Ruszniewski P, Ramdani A, Cadiot G et al: Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 1993; 23: 296–301.